Overall survival (3A) and progression-free survival (3B) in chemotherapy alone versus chemotherapy + bevacizumab arms on Gynecologic Oncology Group 240 [reproduced with permission from Tewari et al. 2014].
bev, bevacizumab; CR, complete response; CI, confidence interval; HR, hazard ratio; mos, months; OS, overall survival; PFS, progression-free survival; RR, response rate.